Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lukas

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Biochemistry|September 15, 2004
Discovery and characterization of a substrate selective p38alpha inhibitorWalter Davidson, Lee Frego, Gregory W Peet, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Infliximab dependency in children with Crohn's diseaseD Duricova, N Pedersen, M Lenicek, et al.
Gut|February 15, 2007
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialW J Sandborn, S B Hanauer, P Rutgeerts, et al.
Nature Materials|October 5, 2021
Enhanced superconductivity and ferroelectric quantum criticality in plastically deformed strontium titanateS Hameed, D Pelc, Z W Anderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 26, 2013
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3Nuruddeen D Lewis, Sokol A Haxhinasto, Shawn M Anderson, et al.
Digestion|February 24, 2006
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working partyN K H de Boer, W Reinisch, A Teml, et al.
Alimentary Pharmacology & Therapeutics|October 9, 2013
The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness methodW Reinisch, Y Chowers, S Danese, et al.
Alimentary Pharmacology & Therapeutics|March 5, 2014
Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicinesF Gomollón, Y Chowers, S Danese, et al.
Plos One|June 27, 2014
A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivoNuruddeen D Lewis, Lori A Patnaude, Josephine Pelletier, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2017
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrenceW Kruis, V Kardalinos, T Eisenbach, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Biochemistry|September 15, 2004
Discovery and characterization of a substrate selective p38alpha inhibitorWalter Davidson, Lee Frego, Gregory W Peet, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Infliximab dependency in children with Crohn's diseaseD Duricova, N Pedersen, M Lenicek, et al.
Gut|February 15, 2007
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trialW J Sandborn, S B Hanauer, P Rutgeerts, et al.
Nature Materials|October 5, 2021
Enhanced superconductivity and ferroelectric quantum criticality in plastically deformed strontium titanateS Hameed, D Pelc, Z W Anderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 26, 2013
Circulating monocytes are reduced by sphingosine-1-phosphate receptor modulators independently of S1P3Nuruddeen D Lewis, Sokol A Haxhinasto, Shawn M Anderson, et al.
Digestion|February 24, 2006
6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working partyN K H de Boer, W Reinisch, A Teml, et al.
Alimentary Pharmacology & Therapeutics|October 9, 2013
The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness methodW Reinisch, Y Chowers, S Danese, et al.
Alimentary Pharmacology & Therapeutics|March 5, 2014
Letter: European Medicines Agency recommendations for allergic reactions to intravenous iron-containing medicinesF Gomollón, Y Chowers, S Danese, et al.
Plos One|June 27, 2014
A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivoNuruddeen D Lewis, Lori A Patnaude, Josephine Pelletier, et al.
Alimentary Pharmacology & Therapeutics|May 26, 2017
Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrenceW Kruis, V Kardalinos, T Eisenbach, et al.
Pageof 7